Arizona Audit Finds $50.9 Million in Opioid Settlement Funds Misused for Prison Hepatitis C Treatment

Arizona's Department of Corrections, Rehabilitation and Reentry may have unlawfully spent more than $50 million from the state's opioid settlement on hepatitis C treatments for prison inmates, according to a new audit from the state auditor general. The findings validate concerns raised nearly two years ago by Attorney General Kris Mayes and highlight ongoing challenges in ensuring that settlement funds reach the communities they were intended to help.

The audit, released Tuesday, found that ADCRR used $50.9 million of opioid settlement money to treat inmates for hepatitis C without providing documentation to demonstrate whether those inmates contracted the virus from intravenous opioid use. The settlement agreement governing Arizona's $1 billion award from opioid manufacturers and distributors specifically requires that funds address the effects of the opioid crisis—and that recipients document how their spending meets that mandate.

The Settlement and Its Restrictions

Arizona secured its $1 billion settlement against opioid makers and distributors in 2021, joining thousands of state and local governments that sought accountability from companies accused of fueling the addiction crisis through deceptive marketing and reckless distribution practices. Like other settlements, Arizona's agreement established strict parameters for how the money could be used.

The agreement requires that settlement funds go toward addressing the effects of the opioid crisis, with specific categories including treatment, prevention, recovery support, and harm reduction. It also mandates detailed reporting to demonstrate compliance. These provisions reflect lessons learned from earlier tobacco settlements, where funds often disappeared into general budgets rather than addressing the public health harms they were meant to mitigate.

The audit found that ADCRR failed to meet these documentation requirements. While hepatitis C can be transmitted through intravenous drug use—and often is among people with substance use disorders—the department could not establish that the inmates treated with settlement funds had actually contracted the virus through opioid use rather than through other transmission routes.

A Pattern of Concerns

Attorney General Mayes first raised alarms about the corrections department's use of opioid settlement funds in September 2024. At that time, her office identified nearly $40 million being spent on hepatitis C treatments for inmates, arguing that this purpose clearly fell outside the settlement's approved uses.

"This opioid money should have gone to address that critical issue," Mayes said then, referring to the broader addiction crisis affecting Arizona communities. Her spokesperson, Richie Taylor, reiterated that position following the audit's release, stating that the money "should have been spent in communities that needed help all along, not used to backfill a budget deficit and other expenses at ADCRR."

The audit's higher figure—$50.9 million rather than the $40 million initially identified—suggests the practice continued and expanded after the attorney general's initial warnings. This persistence raises questions about oversight mechanisms and whether state agencies face meaningful consequences for noncompliance with settlement terms.

Consequences and Implications

The audit's findings carry significant implications for both ADCRR and Arizona's broader opioid settlement administration. Under the terms of the settlement agreement, the state could require the corrections department to return misspent funds. Additionally, noncompliance could jeopardize the department's access to future settlement allocations.

"When Agreement monies are not spent as intended, less monies are available for uses that benefit the State and its residents, such as for approved opioid abatement strategies outlined in the Agreement," the auditor general's report stated. This observation captures the zero-sum nature of settlement fund allocation: every dollar spent on purposes outside the agreement's scope is a dollar unavailable for treatment, prevention, or recovery services.

The findings also carry political weight. Arizona stands out as one of only a handful of states where opioid overdose deaths have continued rising even as they fall across most of the country. According to CDC data released this week, Arizona experienced an increase of 10% or more in overdose deaths compared to 2024—a stark contrast to the national trend of declining fatalities.

National Context of Settlement Accountability

Arizona's audit reflects broader national tensions surrounding opioid settlement accountability. Across the country, state and local governments have received billions of dollars from settlements with manufacturers, distributors, and pharmacies accused of contributing to the crisis. How those funds are spent has become a subject of intense scrutiny and, frequently, dispute.

Some jurisdictions have created dedicated oversight bodies to ensure settlement funds reach approved purposes. Others have integrated the money into general budgets, drawing criticism from advocates who argue that the funds should supplement rather than replace existing spending on addiction services. Philadelphia's recent effort to use settlement money for community revitalization projects in Kensington—while also addressing the overdose crisis—has generated legal challenges and policy debates about what constitutes permissible use.

The Arizona case presents a particularly stark example of potential misuse because the funds appear to have been diverted to a purpose—general inmate healthcare—that would have been funded through other budget mechanisms in the absence of settlement money. This "backfilling" dynamic, where settlement funds replace existing appropriations rather than expanding services, has been a persistent concern among public health advocates.

The Human Cost of Misdirection

Behind the audit's financial findings lie human consequences. Arizona communities continue to experience rising overdose deaths at a time when resources should be flowing toward prevention and treatment. The $50.9 million in question represents thousands of doses of naloxone, months of medication-assisted treatment for opioid use disorder, or comprehensive recovery support services that could have helped Arizonans survive and thrive.

The audit does not suggest that treating hepatitis C in prisons is unimportant. The disease is curable with modern antiviral medications, and treating incarcerated individuals reduces transmission both within facilities and in communities to which inmates eventually return. The question is whether opioid settlement funds—specifically designated to address the opioid crisis—are the appropriate source for that treatment.

Moving Forward

The audit's release places pressure on state officials to respond. Options include requiring ADCRR to repay misspent funds, imposing additional reporting requirements, or restructuring how the department accesses settlement allocations. The attorney general's strong statement suggests her office will push for meaningful accountability rather than symbolic gestures.

For other states, the Arizona audit offers a cautionary tale about the importance of robust oversight mechanisms. Settlement funds represent a finite resource intended to address decades of harm. Every diversion, whether through explicit misuse or gradual mission creep, reduces the capacity to save lives and support recovery.

As the opioid settlement era continues, ensuring that funds reach their intended purposes remains essential to honoring both the legal agreements that generated these resources and the communities still struggling with the crisis's devastating effects.